NASDAQ:REGN

Even the real leaders are light.

LLY up 4% at $1,213.35. REGN up 3% at $775.91. Yeah, totally.

Those are your medical names.

Right, but Arval's 0.6 and 0.4, light participation even in the winners.

New to the buy list.

We are raising our rating on Regeneron Pharmaceuticals' REGN shares to buy from hold.

The company has seen strong growth for its highest revenue generating product, Dupixent, which saw sales rise thirty-eight percent during two Q twenty-six to six billion dollars.

With Dupixent and its other two blockbuster drugs, Libtayo and Praluent, which saw sales grow thirty percent and twenty percent respectively, we expect the company to experience strong growth over the next several quarters.